The global microfluidics market size is expected to reach USD 81.13 Billion in 2030 and register a revenue CAGR of 16.2% during the forecast period. Increasing demand for low volume samples, and Point-of-Care (POC) testing with faster turn-around time, portability, and accuracy are key factors expected to drive market revenue growth during the forecast period. Rising prevalence of chronic diseases coupled with increasing elderly individuals and age-related diseases and high demand for home care is contributing significantly to revenue growth of the market. Demand for microfluidic-based POC devices which perform the combination of several laboratory processes on a single chip is also increasing. Ease of detection procedures in resource-limited impoverished areas is possible as well owing to the reduced cost of each procedure through miniaturization and minimal reagent usage.
The requirement for ambient light-sensitive cameras or immovable desktop scanners makes it difficult to use the existing standard testing such as Enzyme-Linked Immunosorbent Assay (ELISA), which involves time-consuming sample preparation procedures. Microfluidic systems are designed to miniaturize and combine processes of sample preparation, evaluation, detection, and analysis into a single portable chip, making it a time-saving procedure. Moreover, microfluidic-based POC devices can be combined with smartphones, are convenient to use, and are owned by a vast majority of individuals globally, thereby making it easier for mass production and commercialization. Hence, microfluidics-based POC diagnostic tools, known as lab-on-chip POC devices, in the healthcare sector have proven to be a robust and optimal medical technology as these provide various advantages such as quick and accurate analysis, ease of operation, cost-effectiveness, portability, and non-requirement of trained personnel, especially in remote and resource restrained settings. Furthermore, the analysis procedure can be automated, minimizing human involvement and enabling efficient experiment repetition, making it environment- friendly from a disposability perspective.
Request a Sample@ https://www.qyresearchmedical.com/sample/119113
Integrating optics with microfluidic devices can facilitate new functionalities without jeopardizing integrability or convenience. POC devices based on microfluidics as wearable devices with WiFi capabilities, offer the potential to improve healthcare by allowing for easier monitoring, early disease diagnosis, and improved personalization. Biosensing integration with Information and Communication Technologies (ICTs) for eHealth diagnosis has potential for ample growth in various areas, especially biomedical applications such as cancer diagnosis, pregnancy testing, HIV diagnosis, glucose biosensors, and drug administering. Increased Research & Development (R&D) initiatives, drug discovery research, and pharmaceutical and biotechnology research have all contributed to microfluidic market’s recent surge in terms of revenue.
Driver: Rise in demand for faster and accurate point-of-care testing
Point-of-care diagnostics is an integral part of healthcare, especially in the diagnostics of diseases. Microﬂuidics (also known as Lab-on-Chip [LOC] devices) for biosensors and diagnostics has proven to be a robust and optimal medical technology compared to standard laboratory-based testing, especially in demanding and resource-constrained environments. Microfluidic’s user-friendliness and ease of result interpretation have the potential to be an appealing alternative in contexts where experienced healthcare personnel are limited. Moreover, advantages such as portability, accessibility, ease of operation, and reduced process time compared to traditional methods of diagnosis are driving rapid adoption of microfluidic POC testing, and the trend is expected to continue over the forecast period. In addition, rising prevalence of lifestyle-related and infectious diseases, increasing preference for home healthcare POC testing, and use in hospitals during medical emergencies for rapid diagnosis and decision making are expected to drive market revenue growth.
Restraint: Low adoption in some developing countries due to high cost of R&D
High cost of R&D and production of microfluidic devices is a major hurdle for mass production in emerging low-income countries. Current stringent regulatory policies such as the Food and Drug Administration (FDA) approval process for medical devices, which has a major impact on drug delivery, In-vitro Diagnostics (IVD), and pharmaceutical sectors. Furthermore, uncertainty in the approval process largely affects the profitability of the product. Access to advanced healthcare is lacking in some emerging and low-income countries. Furthermore, lack of awareness regarding disease prevention, poor access to information about healthcare, and non-availability of proper healthcare services are other factors expected to restrain market growth to some extent.
The importance of rapid and accurate diagnostic tools for the rapid identification, POC testing, IVD devices, and treatment of COVID-19 infected patients placed microfluidics back in focus. Effective testing and tracing of virus spread were primary requirements for eliminating spread. Advancements in microfluidic technology, portability of devices, need for low volume samples, and support from regulatory bodies to approve microfluidics tests to combat COVID-19 gained prominence. Currently, microfluidics are being used to develop antibody treatments for people diagnosed with particular variants of COVID-19. Microfluidic devices are proving increasingly beneficial in medical research, drug development, and diagnostics. According to a 12 April 2022 published article by Science Daily, researchers at the University of Southern California have designed a 3D printing system for producing microfluidic devices at the microscale for biomedical purposes, which has potential for commercialization. Production of microfluidic devices is labor-intensive, with minute channels, required to be manually etched or molded into a transparent resin chip for testing.
Based on components, global microfluidics market has been segmented into microfluidic chips, micropumps, microneedles, and other components.
Micropump segment revenue is expected to register a steady growth rate during the forecast period. Micropumps are promising as these reduce the dosing size and enable new therapies, thereby improving drug delivery applications. Demand for micropumps is increasing in POC testing centers as these devices require low volume samples and offer a quick turnaround time. Various medical applications for micropumps such as blood transportation through artificial hearts, transdermal insulin administration, hormone therapy, pain and wound-care management, and glucose and medication injection is driving demand. Increased demand in biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and academic and research institutes is expected to boost growth opportunities in the micropump market during the forecast period.
Based on application, global microfluidics market has been segmented into drug delivery, point-of-care diagnostics, pharmaceutical and biotechnology research, clinical diagnostics, and others.
In 2021, the POC diagnostics segment accounted for a significantly large revenue share, owing to increased prevalence of infectious and chronic diseases and high demand for home care. High level of flexibility in terms of functionality and customization in microfluidics enables combining chemical and biological laboratories functions into a variety of on-chip diagnostic modules, making the devices an ideal alternative for resource restrained areas. Low-cost and need for small samples for research is boosting demand for microfluidic-based devices. Microfluidic devices offer significant advantages compared to the traditional testing equipment in terms of mobility, accessibility, and ease of operation owing to small and compact structure. Patients can utilize lab-on-chips to monitor and assess various health-related conditions and aspects in the comfort of their home. Users can monitor electrolytes during diuretic medication and serum creatinine and blood urea nitrogen levels for chronic kidney disease. Incorporating microfluidics in wearable technologies offers ample growth potential, especially in healthcare applications.
Based on material, global microfluidics market has been segmented into polymer, silicone, glass, and other materials.
Polymer segment revenue is expected to register a steady growth rate during the forecast period. Flexibility in molding and pressing, ease of procurement, and biocompatibility has boosted demand for polymer (also known as Polydimethylsiloxane or PDMS for short). PDMS is a commonly utilized material in the production of microfluidic devices. Various characteristics of PDMS such as low cost, transparency, elasticity, and gas permeability makes it ideal for cell culturing and processing. Furthermore, hybrids of silicon, glass, and polymer materials can be used in microfluidic devices, allowing for increased usability.
North America accounted for largest revenue share in global microfluidics market in 2021, owing to well-established healthcare system, governmental and financial support, use of advanced technologies, and high adoption of innovative treatments in countries in the region. The US is one of the prime destinations for R&D, with a significantly high budget. The presence of various leading research institutes and their active participation in the development of innovative microfluidic devices is expected to contribute to revenue growth of the market in the region. The engagement of various major research institutes as well as their active participation in the development of more innovative microfluidic devices is expected to drive market growth.
High value funding for research into microfluidics and related technologies in Europe and focus on medical and non-medical research is a key factor supporting growth of microfluidics market in the region. The market in Asia Pacific is expected to register a steady revenue growth during the forecast period. Increased demand for POC testing, rising prevalence of chronic diseases, and supportive government norms and efforts are some key factors contributing to market growth. China, Japan, and India are the leading revenue contributors to the Asia Pacific microfluidics market.
Competitive landscape of global microfluidics market is moderately fragmented with many key companies operating at global and regional levels. Major companies are engaged in research and development initiatives and testing, and entering into alliances to develop and introduce more novel and innovative products and devices.
Some major companies in the global market report include uFluidix, Nanōmix, Inc., Quidel Corporation, biosurfit SA, Abbott, Illumina, Inc., Abaxis, NanoEntek, PerkinElmer Inc., and Bio-Rad Laboratories, Inc.
- On 24 March 2022, Miroculus announced the launch of Miro Canvas, which is a compact and easy-to-use digital microfluidics platform to automate complex Next-Generation Sequencing (NGS) sample preparation protocols.
- On 1 April 2022, engineering researchers from Florida Atlantic University’s College of Engineering and Computer Science developed an easy-to-operate and inexpensive microfluidic chip for sperm selection to treat infertility. The device is designed to isolate healthy sperms from the collecting chamber, while simultaneously reducing contamination by deformed or dead sperm cells.
Segments Covered in the report
This report offers historical data and forecasts revenue growth at a global, regional, and country level, and provides analysis of market trends in each of sub-segments from 2022 to 2030. For the purpose of this report, Reports and Data has segmented global microfluidics market based on components, application, material, and region:
Microfluidics Market Report Scope
Segments covered By Components Outlook, Application Outlook, Material Outlook, Regional Outlook
By Components Outlook
By Application Outlook
Point-of-Care (POC) Diagnostics
Pharmaceutical and Biotechnology Research
By Material Outlook
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://www.qyresearchmedical.com/report/checkout/119113/1500
You can place an order or ask any questions, please feel free to contact [email protected] | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/